FDA Accepts Merck Application for Expanded RSV Protection in Young Children

The U.S. FDA has accepted Merck's supplemental application to expand the indication for ENFLONSIA (clesrovimab-cfor). This aims to provide extended protection against severe Respiratory Syncytial Virus (RSV) disease for children under two years old during their second RSV season. The regulatory action seeks to lessen the impact of RSV on families and healthcare systems.